Clinical Trial Detail

NCT ID NCT01286987
Title Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements yes
Sponsors BioMarin Pharmaceutical
Indications

pancreatic cancer

lung small cell carcinoma

Ewing sarcoma

ovarian cancer

prostate cancer

Advanced Solid Tumor

breast cancer

Therapies

Talazoparib

Age Groups: adult senior

Additional content available in CKB BOOST